Biologic breakdown

Krader, Cheryl Guttman
April 2010
Dermatology Times;Apr2010 Advances on Psoriasis Suppl, Vol. 31, p8
Trade Publication
The article reports on the results of the Active Comparative (CNTO1275/Enbrel) Psoriasis Trial (ACCEPT), which randomized 903 patients into three groups to receive subcutaneous ustekinumab given in two doses. According to doctor Alan Menter, the superiority of ustekinumab shows the promise of this novel class of interleukin (IL)-12/IL-23 antagonists for the treatment of psoriasis. Menter also stated that the results of the trials are consistent with other studies.


Related Articles

  • Promise for psoriasis. Jesitus, John // Dermatology Times;Feb2011, Vol. 32 Issue 2, p34 

    The article discusses the approval of the phase 2 clinical trial of Janus kinase (JAK) inhibitor, a drug which can be used for the treatment of chronic moderate to severe psoriasis. According to pharmacological investigators, JAK has passed the safety and efficacy tests which was conducted in...

  • Preclinical research in drug development. Honek, Jennifer // Medical Writing;Dec2017, Vol. 26 Issue 4, p5 

    The process of developing a novel drug is time consuming and costly. To increase the chances of successfully completing a clinical trial leading to the approval of a new drug, the choice of appropriate preclinical models is of utmost importance. Identifying a safe, potent, and efficacious drug...

  • new Data Bring Biologics for Psoriasis Closer to Market. Krause, Carey // Chemical Market Reporter;3/31/2003, Vol. 263 Issue 13, p7 

    Reports on the release of a clinical trial data for several psoriasis drugs in the U.S. Details on the mechanism of action and the relative benefits of the drugs; Emphasis on the Psoriasis Area and Severity Index efficacy standard; Concerns over T-cell reductions in Amevive-treated patients.

  • The Olivieri Report--A Compelling Study of the Growing Tensions in Clinical Research. Di Norcia, Vincent // Science & Engineering Ethics;Jan2003, Vol. 9 Issue 1, p125 

    Comments on the "Olivieri Report," an inquiry conducted by the Canadian Association of University regarding a dispute over researcher Nancy Olivieri's investigation on a new drug therapy. Concerns over the commercialization of clinical trials of new drugs; Medical and scientific issues tackled...

  • A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology. Comets, Emmanuelle; Zohar, Sarah // Clinical Pharmacokinetics;2009, Vol. 48 Issue 6, p387 

    Background and objective: During the drug development process, phase I trials are the first occasion to study the pharmacokinetics of a drug. They are performed in healthy subjects, or in patients in oncology, and are designed to determine a safe and acceptable dose for the later phases of...

  • Biotech News Round-up.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p37 

    The article offers news briefs related to biotechnological developments. The phase III study of Amgen Inc. shows that anemia drug Aranesp produced a higher death rate compared to placebo. The phase III data of Schwarz Pharma shows that rotigotine has offered a statistically significant and...

  • Synchrotron contributing to innovative drug development.  // Australasian Biotechnology;Jul2015, Vol. 25 Issue 2, p20 

    The article reports on the role of research facility the Australian Synchrotron in facilitating the advance of world-class disease and drug research through local drug trials. Topics include the Australian biomedical research community's ability to attract international pharmaceutical...

  • Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses. Chiang, A. P.; Butte, A. J. // Clinical Pharmacology & Therapeutics;Nov2009, Vol. 86 Issue 5, p507 

    Drug repositioning refers to the discovery of alternative uses for drugs—uses that are different from that for which the drugs were originally intended. One challenge in this effort lies in choosing the indication for which a drug of interest could be prospectively tested. We...

  • Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis. Anderko, Marian; Triviño, Francisco José Navarro; Sharples, Charlotte L // Clinical, Cosmetic & Investigational Dermatology;Sep2019, Vol. 12, p699 

    This article presents real-world experience of the effectiveness of calcipotriol (50 μg/g)/betamethasone dipropionate (0.5 mg/g) (Cal/BD) aerosol foam formulation in three cases of scalp psoriasis, and briefly reviews the literature relating to Cal/BD topical therapy in adults with scalp...

  • ADVANCED. Brodalumab demonstrates positive results in plaque psoriasis study.  // Dermatology Times;Jun2014, Vol. 35 Issue 6, p10 

    The article reports that phase 3 trial of the drug brodalumab (AMG 827) for treating patients with moderate-to-severe plaque psoriasis has shown positive results, meeting primary and secondary endpoints.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics